[1] Huang L, Guo Z, Wang F, et al. KRAS mutation: from undruggable to druggable in cancer[J]. Signal Transduction and Targeted Therapy, 2021, 6(1): 386. 

[2] Reck M, Carbone D P, Garassino M, et al. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches[J].  Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2021, 32(9): 1101-1110. 

[3] Imyanitov E N, Iyevleva A G, Levchenko E V. Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives[J]. Critical Reviews in Oncology/Hematology, 2021,  157(10): 194. 

[4] Morshedzadeh F, Abbaszadegan M R, Peymani M, et al. KRAS mutations detection methodology: from RFLP to CRISPR/Cas based methods[J]. Functional & Integrative Genomics, 2024, 24(5): 183. 

[5] Ye P, Cai P, Xie J, et al. Reliability of digital PCR in detecting KRAS mutation in colorectal cancer using plasma sample: A systematic review and meta-analysis[J]. Medicine, 2020, 99(28): e21171. 

[6] Lyu N, Rajendran V K, Li J, et al. Highly specific detection of KRAS single nucleotide polymorphism by asymmetric PCR/SERS assay[J]. The Analyst, 2021, 146(18): 5714-5721.

[7] Lim T K H, Skoulidis F, Kerr K M, et al. KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing[J]. Lung Cancer (Amsterdam, Netherlands), 2023, 184(1): 107293. 

[8] Rosell R, Codony-Servat J, González J, et al. KRAS G12Cmutant driven non-small cell lung cancer (NSCLC)[J]. Critical Reviews in Oncology/Hematology, 2024, 195(10): 228. 

[9] de Langen A J, Johnson M L, Mazieres J, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial[J].  Lancet (London, England), 2023, 401(10378): 733-746. 

[10] Guo M Z, Marrone K A, Spira A, et al. Adagrasib: a novel inhibitor for KRASG12C-mutated non-small-cell lung cancer[J]. Future Oncology (London, England), 2023, 19(15): 1037-1051. 

[11] Ibrahim R, Saleh K, Chahine C, et al. KRASG12C mutation in metastatic colorectal cancer: a new target[J]. Future Oncology (London,  England), 2023, 19(24): 1641-1643. 

[12] Awad M M, Liu S, Rybkin I I, et al. Acquired Resistance to KRASG12C Inhibition in Cancer[J]. The New England Journal of Medicine, 2021, 384(25): 2382-2393. 

[13] Tani T, Kitajima S, Conway E B, et al. KRAS G12C inhibition and innate immune targeting[J]. Expert Opinion on Therapeutic Targets,  2021, 25(3): 167-174. 

[14] Chmielewska I, Krawczyk P, Grenda A, et al. Breaking the “Undruggable” Barrier: Anti-PD-1/PD-L1 Immunotherapy for NonSmall Cell Lung Cancer Patients with KRAS Mutations-A Comprehensive Review and Description of Single Site Experience[J]. Cancers, 2023,  15(14): 3732. 

[15] Riedl J M, Fece de la Cruz F, Lin J J, et al. Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors[J]. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2025: S0923-7534(25)：52-3. 

[16] Mahadevan K K, McAndrews K M, LeBleu V S, et al.  KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+  T cells[J]. Cancer Cell, 2023, 41(9): 1606-1620.e8. 

[17] Zhou C, Li C, Luo L, et al. Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12Dmutant cancer[J]. Cancer Cell, 2024, 42(7): 1286-1300.e8. 

[18] Luo J. KRAS mutation in pancreatic cancer[J]. Seminars in Oncology, 2021, 48(1): 10-18. 

[19] Lu D, Chen Y, Jiang M, et al. KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors[J]. Nature Communications, 2023, 14(1): 6389. 

[20] Kumar G, Madka V, Singh A, et al. Naproxen inhibits spontaneous lung adenocarcinoma formation in KrasG12V mice[J].  Neoplasia (New York, N.Y.), 2021, 23(6): 574-583. 

[21] West H J, McCleland M, Cappuzzo F, et al. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations:  subgroup results from the phase III IMpower150 trial[J]. Journal for Immunotherapy of Cancer, 2022, 10(2): e003027. 

[22] Rossi S, Pagliaro A, Finocchiaro G, et al. Response to firstline pembrolizumab in metastatic KRAS-mutated non-small-cell lung cancer[J]. Future Oncology (London, England), 2024, 20(7): 373- 380. 

[23] Wang X, Wang W, Zou S, et al. Combination therapy of KRAS G12V mRNA vaccine and pembrolizumab: clinical benefit in patients with advanced solid tumors[J]. Cell Research, 2024, 34(9): 661-664. 

[24] Zhu C, Guan X, Zhang X, et al. Targeting KRAS mutant cancers: from druggable therapy to drug resistance[J]. Molecular Cancer, 2022, 21(1): 159.